S Nordling
Overview
Explore the profile of S Nordling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
1661
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Engen A, Lie X, Noren T, Nordling S, Norgaard K
Value Health
. 2016 May;
17(7):A673-4.
PMID: 27202472
No abstract available.
2.
Nordling S, Anttila V, Noren T, Cockburn E
Value Health
. 2016 May;
17(7):A670.
PMID: 27202459
No abstract available.
3.
4.
Seppanen H, Juuti A, Mustonen H, Haapamaki C, Nordling S, Carpelan-Holmstrom M, et al.
Scand J Surg
. 2016 May;
106(1):54-61.
PMID: 27130378
Objectives: Since the early 1990s, low long-term survival rates following pancreatic surgery for pancreatic ductal adenocarcinoma have challenged us to improve treatment. In this series, we aim to show improved...
5.
Hellgren J, Cervin A, Nordling S, Bergman A, Cardell L
Allergy
. 2009 Dec;
65(6):776-83.
PMID: 19958315
Unlabelled: The common cold and allergic rhinitis constitute a global health problem that affects social life, sleep, school and work performance and is likely to impose a substantial economic burden...
6.
Hofling M, Ma L, Sahlin L, Haglund C, Nordling S, von Schoultz B, et al.
Climacteric
. 2008 Nov;
12(1):72-9.
PMID: 19003632
Objectives: To analyze the expression of the androgen receptor(AR) and syndecan-1 in breast tissue during long-term hormonal treatment in cynomolgus monkeys. Methods: Sixty oophorectomized macaques were randomized to receive either...
7.
Lundin M, Nordling S, Lundin J, Haglund C
Oncology
. 2008 Jan;
72(5-6):403-9.
PMID: 18196927
Objective: The extracellular matrix glycoprotein tenascin-C has been proposed as a tumor marker with prognostic significance in many cancer forms, but in colorectal cancer, reported results have been controversial. The...
8.
Linder N, Haglund C, Lundin M, Nordling S, Ristimaki A, Kokkola A, et al.
J Clin Pathol
. 2006 Aug;
59(9):965-71.
PMID: 16935971
Background: Xanthine oxidoreductase (XOR) is a key enzyme in the degradation of DNA, RNA and high-energy phosphates. About half of the patients with breast cancer have a decrease in XOR...
9.
Mrena J, Wiksten J, Nordling S, Kokkola A, Ristimaki A, Haglund C
J Clin Pathol
. 2006 May;
59(6):618-23.
PMID: 16731602
Background And Aim: Matrix metalloproteinases (MMPs) MMP-2 and MMP-9 can degrade type IV collagen of extracellular matrix and basal membranes. As cyclo-oxygenase-2 (COX-2) has been shown to activate MMPs, creating...
10.
Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C
J Clin Pathol
. 2006 Feb;
59(4):382-6.
PMID: 16467169
Background: Cyclooxygenase-2 (COX-2) overexpression is related to poor outcome in several cancers. COX-2 is upregulated in 42-90% of pancreatic ductal adenocarcinomas and is a potential target for chemotherapy. Earlier studies...